Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eshleman, J. S.
Right arrow Articles by Sarkaria, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eshleman, J. S.
Right arrow Articles by Sarkaria, J. N.
[Cancer Research 62, 7291-7297, December 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Inhibition of the Mammalian Target of Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy1

Jeffrey S. Eshleman, Brett L. Carlson, Ann C. Mladek, Brian D. Kastner, Kathleen L. Shide and Jann N. Sarkaria2

Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905

The mammalian target of rapamycin (mTOR) modulates key signaling pathways that promote uncontrolled proliferation of glioblastoma multiforme (GBM). Because rapid tumor proliferation may contribute to the clinical radioresistance of GBM tumors, the combination of rapamycin, a selective mTOR inhibitor, and radiation was studied in vitro and in vivo in a GBM model. In monolayer cultures of U87 and SKMG-3 cells, rapamycin had no impact on radiation sensitivity. In contrast, rapamycin significantly enhanced the efficacy of fractionated radiation of established U87 xenografts in nude mice. Similar effects were seen in U87 spheroids treated with rapamycin and radiation, which suggests that the sensitizing effects of this drug are dependent on disruption of mTOR signaling pathways specifically within tumor cells. Inhibition of these signaling pathways can lead to inhibition of G1-specific cyclin-dependent kinase activities, and this could contribute to the sensitizing effects of rapamycin. Consistent with this idea, roscovitine, a specific cyclin-dependent kinase inhibitor, also enhanced the efficacy of fractionated radiation in U87 spheroids. These data demonstrate that inhibition of tumor proliferation does not diminish the efficacy of fractionated radiation and suggest that disruption of key signal transduction pathways may significantly enhance the effectiveness of radiation therapy in malignant gliomas.




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
S. Braunstein, M. L. Badura, Q. Xi, S. C. Formenti, and R. J. Schneider
Regulation of Protein Synthesis by Ionizing Radiation
Mol. Cell. Biol., November 1, 2009; 29(21): 5645 - 5656.
[Abstract] [Full Text] [PDF]

Home page
 DMMHome page
M. C. Ljungberg, C. N. Sunnen, J. N. Lugo, A. E. Anderson, and G. D'Arcangelo
Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia
Dis. Model. Mech., July 1, 2009; 2(7-8): 389 - 398.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. W. Ronellenfitsch, D. P. Brucker, M. C. Burger, S. Wolking, F. Tritschler, J. Rieger, W. Wick, M. Weller, and J. P. Steinbach
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
Brain, June 1, 2009; 132(6): 1509 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. D. Murphy, A. C. Spalding, Y. R. Somnay, S. Markwart, M. E. Ray, and D. A. Hamstra
Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
Clin. Cancer Res., January 15, 2009; 15(2): 589 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Opel, M.-A. Westhoff, A. Bender, V. Braun, K.-M. Debatin, and S. Fulda
Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis
Cancer Res., August 1, 2008; 68(15): 6271 - 6280.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Yang, M. J. Clarke, B. L. Carlson, A. C. Mladek, M. A. Schroeder, P. Decker, W. Wu, G. J. Kitange, P. T. Grogan, J. M. Goble, et al.
PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel
Clin. Cancer Res., June 15, 2008; 14(12): 3993 - 4001.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. S. Chen, L. J. Zhou, M. Entin-Meer, X. Yang, M. Donker, Z. A. Knight, W. Weiss, K. M. Shokat, D. Haas-Kogan, and D. Stokoe
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma
Mol. Cancer Ther., April 1, 2008; 7(4): 841 - 850.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Kunnumakkara, P. Diagaradjane, S. Guha, A. Deorukhkar, S. Shentu, B. B. Aggarwal, and S. Krishnan
Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to {gamma}-Radiation by Targeting Nuclear Factor-{kappa}B-Regulated Gene Products
Clin. Cancer Res., April 1, 2008; 14(7): 2128 - 2136.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Ziegler, A. L. Kung, and M. W. Kieran
Anti-Apoptosis Mechanisms in Malignant Gliomas
J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Kuhn, S. M. Chang, P. Y. Wen, T. F. Cloughesy, H. Greenberg, D. Schiff, C. Conrad, K. L. Fink, H. I. Robins, M. Mehta, et al.
Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma
Clin. Cancer Res., December 15, 2007; 13(24): 7401 - 7406.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Li, Y. Wang, E. Kim, P. Beemiller, C.-Y. Wang, J. Swanson, M. You, and K.-L. Guan
Bnip3 Mediates the Hypoxia-induced Inhibition on Mammalian Target of Rapamycin by Interacting with Rheb
J. Biol. Chem., December 7, 2007; 282(49): 35803 - 35813.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Lefranc, V. Facchini, and R. Kiss
Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas
Oncologist, December 1, 2007; 12(12): 1395 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Beeram, Q-T. Tan, R. Tekmal, D Russell, A Middleton, and L. deGraffenried
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
Ann. Onc., August 1, 2007; 18(8): 1323 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Hong, L. Lei, B. Kunert, R. Naredla, S. E. Applequist, A. Grandien, and R. Glas
Tripeptidyl-peptidase II Controls DNA Damage Responses and In vivo {gamma}-Irradiation Resistance of Tumors
Cancer Res., August 1, 2007; 67(15): 7165 - 7174.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S.-H. Sin, D. Roy, L. Wang, M. R. Staudt, F. D. Fakhari, D. D. Patel, D. Henry, W. J. Harrington Jr, B. A. Damania, and D. P. Dittmer
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
Blood, March 1, 2007; 109(5): 2165 - 2173.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. E. Pelloski, E Lin, L. Zhang, W.K. A. Yung, H. Colman, J.-L. Liu, S. Y. Woo, A. B. Heimberger, D. Suki, M. Prados, et al.
Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma.
Clin. Cancer Res., July 1, 2006; 12(13): 3935 - 3941.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. M. Albert, K. W. Kim, C. Cao, and B. Lu
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer
Mol. Cancer Ther., May 1, 2006; 5(5): 1183 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, et al.
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
J. Clin. Oncol., August 10, 2005; 23(23): 5294 - 5304.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Liu, A. Howes, J. Lesperance, W. B. Stallcup, C. A. Hauser, K. Kadoya, R. G. Oshima, and R. T. Abraham
Antitumor Activity of Rapamycin in a Transgenic Mouse Model of ErbB2-Dependent Human Breast Cancer
Cancer Res., June 15, 2005; 65(12): 5325 - 5336.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Lefranc, J. Brotchi, and R. Kiss
Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis
J. Clin. Oncol., April 1, 2005; 23(10): 2411 - 2422.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Wu, D. C. Birle, and I. F. Tannock
Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts
Cancer Res., April 1, 2005; 65(7): 2825 - 2831.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. B. Heimberger, E. Wang, E. C. McGary, K. R. Hess, V. K. Henry, T. Shono, Z. Cohen, J. Gumin, R. Sawaya, C. A. Conrad, et al.
Mechanisms of action of rapamycin in gliomas
Neuro-oncol, January 1, 2005; 7(1): 1 - 11.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. A. deGraffenried, W. E. Friedrichs, D. H. Russell, E. J. Donzis, A. K. Middleton, J. M. Silva, R. A. Roth, and M. Hidalgo
Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity
Clin. Cancer Res., December 1, 2004; 10(23): 8059 - 8067.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. K. Park, Y. M. Chung, B.-G. Kim, Y.-A Yoo, B.-S. Yang, J. S. Kim, and Y. D. Yoo
N'-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester enhances radiation-induced cell death by targeting Bcl-2 against human lung carcinoma cells
Mol. Cancer Ther., April 1, 2004; 3(4): 403 - 407.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. M. Tirado, S. Mateo-Lozano, S. Sanders, L. E. Dettin, and V. Notario
The PCPH Oncoprotein Antagonizes the Proapoptotic Role of the Mammalian Target of Rapamycin in the Response of Normal Fibroblasts to Ionizing Radiation
Cancer Res., October 1, 2003; 63(19): 6290 - 6298.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.